Compare/OpenMythos vs ORAC-NT

AI tool comparison

OpenMythos vs ORAC-NT

Which one should you ship with? Here is the side-by-side panel verdict, pricing read, reviewer split, and community vote comparison.

O

Research & Open Source

OpenMythos

Open-source PyTorch reconstruction of Claude Mythos' suspected architecture

Ship

75%

Panel ship

Community

Paid

Entry

OpenMythos is a PyTorch reconstruction of the suspected architecture underlying Anthropic's Claude Mythos model, built entirely from published research. Creator Kye Gomez hypothesizes that Mythos uses a Recurrent-Depth Transformer (RDT) — where a subset of transformer layers loops multiple times per forward pass with shared weights rather than stacking unique layers. This allows the model to simulate "thinking" by iterating over the same compute graph, giving it emergent chain-of-thought behavior without explicit CoT prompting. At 770M parameters, the OpenMythos implementation reportedly matches the downstream quality of a 1.3B standard transformer on benchmarks. The architecture combines Multi-Latent Attention for memory compression, LTI (Linear Time-Invariant) stability constraints to prevent training instability during recurrence, Mixture of Experts routing for specialization, and Adaptive Computation Time (ACT) halting to decide when to stop looping per token. The project exploded on GitHub within days — 6.2k stars, 1.2k forks — and Kye's X announcement drove massive engagement (4.1k likes, 4.5k reposts). Community reaction is genuinely divided: AI researchers calling it "the most sophisticated reverse-engineering of an LLM architecture I've seen" while Anthropic has not confirmed or denied any of the architectural claims. This is an educated speculation backed by real engineering, not a marketing exercise.

O

Research

ORAC-NT

MedChem copilot that blocks toxic molecular modifications before you make them

Ship

75%

Panel ship

Community

Paid

Entry

ORAC-NT is an open-source medicinal chemistry copilot for early-stage drug discovery. Unlike general-purpose AI tools, it actively blocks synthetically infeasible or toxic molecular modifications — it won't just suggest them — and explains exactly why each transformation is rejected before proposing valid alternatives. The tool provides guided transformation pathways for common medicinal chemistry operations: halogenation, methylation, scaffold simplification, bioisosteric replacement, and solubility optimization. Each step generates an audit trail formatted for regulatory documentation, addressing a real gap in AI-assisted drug design where there's no clear chain of reasoning for a discovery team's choices. The target user is a medicinal chemist doing early lead optimization who wants AI assistance but can't afford hallucinated suggestions. ORAC-NT's guardrail-first design philosophy means it says 'no' often, with explanation — the opposite of most AI tools that optimize for appearing helpful.

Decision
OpenMythos
ORAC-NT
Panel verdict
Ship · 3 ship / 1 skip
Ship · 3 ship / 1 skip
Community
No community votes yet
No community votes yet
Pricing
Open Source (Apache 2.0)
Open Source / Cloud tier (pricing TBD)
Best for
Open-source PyTorch reconstruction of Claude Mythos' suspected architecture
MedChem copilot that blocks toxic molecular modifications before you make them
Category
Research & Open Source
Research

Reviewer scorecard

Builder
80/100 · ship

Whether or not Anthropic actually uses this architecture, the RDT implementation itself is genuinely impressive engineering. The ACT halting mechanism and LTI stability constraints are clever solutions to problems anyone trying to build reasoning models will face. Fork-worthy regardless of the Mythos speculation.

80/100 · ship

The regulatory audit trail feature alone makes this worth evaluating for any pharma team using AI. The FDA is going to want documentation on AI-assisted design decisions, and ORAC-NT is the only open-source tool I've seen that generates that output by design rather than as an afterthought.

Skeptic
45/100 · skip

This is reverse engineering based on vibes and published papers, not leaked weights or verified architecture docs. Anthropic hasn't confirmed a thing. The 770M benchmark comparisons are cherrypicked and the '1.3B equivalent quality' claim needs independent reproduction. Intellectually interesting, empirically unverified.

45/100 · skip

Drug discovery is a domain where a wrong answer has real stakes, and 'open source with a paid cloud tier' is not how serious pharma teams procure safety-critical software. Until this has been validated against known drug series and peer-reviewed, treating it as anything other than a research prototype would be reckless.

Futurist
80/100 · ship

Regardless of whether Mythos actually is an RDT, this project demonstrates that open-source researchers can meaningfully reconstruct competitive reasoning architectures from scratch. That capability gap between frontier labs and open-source is closing faster than most realize.

80/100 · ship

AI in drug discovery has mostly been a hype layer on top of existing cheminformatics. ORAC-NT's approach — domain-specific guardrails, explainability, audit trails — is what responsible AI deployment actually looks like in high-stakes science. This design pattern will propagate to other regulated domains.

Creator
80/100 · ship

A 6.2k star project in two days means something hit a nerve. The documentation is excellent — clear architecture diagrams, detailed training notes, working code. Even if the Mythos speculation is wrong, this is a model for how to share research engineering properly.

80/100 · ship

The UX philosophy here is fascinating from a design perspective: an AI tool that's deliberately more restrictive than helpful. That's a radical choice that goes against every growth metric. But in professional scientific contexts, trust comes from knowing the tool will say no to bad ideas. That's a design principle worth stealing.

Weekly AI Tool Verdicts

Get the next comparison in your inbox

New AI tools ship daily. We compare them before you waste an afternoon.

Bookmarks

Loading bookmarks...

No bookmarks yet

Bookmark tools to save them for later